Back to results
US 9,427,413 B2Granted
Uses of hypoxia-inducible factor inhibitors
AssigneeOncoimmune, Inc.
InventorsYang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Claims3
A method of reducing self-renewal of acute myeloid leukemia (AML) cancer stem cells in a subject with post-remission AML, without adverse effect on hematopoietic stem cells (HSCs),
- wherein said method consists of administering echinomycin and a pharmaceutically acceptable carrier to a subject in need thereof, and
- wherein said administration results in a serum concentration of echinomycin ranging from 0.01 nM to 5 nM.
Dependencies are inferred from the claim text.